Key result
A joint FDA and CRCG workshop explored and recommended best practices for utilizing model-integrated evidence to assess bioequivalence of long-acting injectable and implantable generic drug products.
Why the study?
There was a need to explore, identify, and recommend best practices on utilizing model-integrated evidence for bioequivalence assessment of long-acting injectable and implantable drug products.
This workshop report outlines best practices and challenges in using model-integrated evidence for bioequivalence assessments of generic long-acting injectable and implantable products.
Answers are grounded in this paper and cite their sources.
Supports model-based bioequivalence frameworks for long-acting injectables; leaves open regulatory adoption pending validation studies.
On November 30, 2021, the US Food and Drug administration (FDA) and the Center for Research on Complex Generics (CRCG) hosted a virtual public workshop titled "Establishing the Suitability of Model-Integrated Evidence (MIE) to Demonstrate Bioequivalence for Long-Acting Injectable and Implantable (LAI) Drug Products." This workshop brought relevant parties from the industry, academia, and the FDA in the field of modeling and simulation to explore, identify, and recommend best practices on utilizing MIE for bioequivalence (BE) assessment of LAI products. This report summerized presentations and panel discussions for topics including challenges and opportunities in development and assessment of generic LAI products, current status of utilizing MIE, recent research progress of utilizing MIE in generic LAI products, alternative designs for BE studies of LAI products, and model validation/verification strategies associated with different types of MIE approaches.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2023) studied Bioequivalence for long-acting injectable and implantable drug products. Model-Integrated Evidence (MIE) was evaluated. A joint FDA and CRCG workshop explored and recommended best practices for utilizing model-integrated evidence to assess bioequivalence of long-acting injectable and implantable generic drug products.
Synapse has enriched 10 related papers. Consider them for comparative context: